At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Midazolam +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Cyclosporine on the Pharmacokinetics of LY3502970 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Midazolam, LY3502970, and 1 other intervention for Healthy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartOct 2022
Primary CompletionJan 2023
TodayJul 2026
First PostedOct 10, 2022
Enrollment StartOct 17, 2022
Primary CompletionJan 17, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.7 years ago
Interventions
Midazolamdrug
Administered orally.
LY3502970drug
Administered orally.
Cyclosporinedrug
Administered orally.